```html

Familial Xanthomatosis: A Complete Medical Guide

Overview

Familial xanthomatosis (also called hereditary xanthomatosis or familial hypercholesterolemia‑related xanthomatosis) is a rare genetic disorder characterized by the development of yellowish, cholesterol‑rich skin lesions called xanthomas. These deposits are most often found on the tendons, elbows, knees, and around the eyes, but they can appear on many other parts of the body. The condition results from lifelong elevations of low‑density lipoprotein cholesterol (LDL‑C) due to inherited defects in the LDL‑receptor pathway.

While the term “familial” indicates an autosomal‑dominant inheritance pattern (most commonly LDLR, APOB, or PCSK9 mutations), a recessive form exists (autosomal recessive hypercholesterolemia) that can be more severe.

• Who it affects: Both males and females; symptoms often appear in childhood or early adulthood.
• Prevalence: Heterozygous familial hypercholesterolemia (the most common cause of familial xanthomatosis) occurs in about 1 in 250–300 people worldwide, making it one of the most common monogenic disorders. However, clinically evident xanthomas develop in only a subset—estimated 10‑20 % of carriers—depending on LDL‑C levels and treatment history.<sup>[1,2]</sup>

Symptoms

Xanthomas are the hallmark, but the disease can present with a variety of systemic findings related to high cholesterol.

Tendon (tuberous) xanthomas

• Location: Extensor tendons of the hands, elbows, knees, and Achilles tendon.
• Appearance: Firm, painless, yellow‑orange nodules that may gradually enlarge.

Plane (flat) xanthomas

• Flat, slightly raised lesions on the trunk, shoulders, or eyelids (often called xanthelasma).

Eruptive xanthomas

• Small, red‑yellow papules that appear suddenly on the buttocks, shoulders, and extensor surfaces, usually when triglycerides are also markedly elevated.

Palmar and plantar xanthomas

• Yellowish plaques on the palms or soles; may be mistaken for eczema.

Systemic signs

• Premature atherosclerotic cardiovascular disease (ASCVD) – early‑onset coronary artery disease, myocardial infarction, stroke.
• Peripheral artery disease causing claudication.
• Arcus corneae (gray‑white ring around the cornea) before age 45.

Other dermatologic findings

• Hyperpigmented or ulcerated lesions if xanthomas become traumatized.

Causes and Risk Factors

Familial xanthomatosis is fundamentally a disorder of cholesterol metabolism.

Genetic causes

• LDLR gene mutations: Impaired or absent LDL‑receptor function (≈85 % of cases).
• APOB mutations: Defective apolipoprotein B‑100 reduces LDL binding to its receptor.
• PCSK9 gain‑of‑function mutations: Accelerate LDL‑receptor degradation.
• Rare recessive genes: LDLRAP1 (autosomal recessive hypercholesterolemia).

Non‑genetic risk modifiers

• Diet high in saturated fats and trans fats – worsens LDL‑C levels.
• Obesity and metabolic syndrome – can coexist and raise triglycerides, precipitating eruptive xanthomas.
• Smoking – accelerates atherosclerosis.
• Physical inactivity – contributes to higher LDL‑C and earlier cardiovascular events.

Who is at greatest risk?

• Individuals with a first‑degree relative diagnosed with familial hypercholesterolemia or with visible xanthomas.
• People with LDL‑C > 190 mg/dL (≈5 mmol/L) from a young age.
• Patients who have not been on cholesterol‑lowering therapy since childhood.

Diagnosis

Diagnosis combines clinical evaluation, biochemical testing, and genetic analysis.

Clinical examination

• Identification of characteristic xanthomas (tendon, plane, eruptive, palmar/plantar).
• Assessment for arcus corneae and other stigmata of hypercholesterolemia.

Laboratory tests

• Lipid profile: Fasting LDL‑C, total cholesterol, HDL‑C, triglycerides. LDL‑C > 190 mg/dL in adults or > 160 mg/dL in children strongly suggests FH.
• Liver function tests – baseline before starting statins.
• Thyroid panel – to exclude secondary hyperlipidemia.

Imaging

• Ultrasound of tendons: Confirms depth of tendon xanthomas.
• Coronary artery calcium (CAC) scoring or CT angiography: Evaluates subclinical atherosclerosis.

Genetic testing

• Targeted sequencing of LDLR, APOB, PCSK9 (and optionally LDLRAP1) can confirm the diagnosis.
• Guides cascade screening of family members.

Diagnostic criteria

The Dutch Lipid Clinic Network (DLCN) score remains widely used. A score ≥ 8 points indicates definite familial hypercholesterolemia, which correlates with a high likelihood of xanthomatosis.

Treatment Options

Management aims to lower LDL‑C to reduce both xanthoma size and cardiovascular risk.

Pharmacologic therapy

• Statins (e.g., rosuvastatin, atorvastatin): First‑line; reduce LDL‑C by 30‑50 %.
• Ezetimibe: Blocks intestinal cholesterol absorption; adds ~15‑20 % LDL‑C reduction when combined with statins.
• PCSK9 inhibitors (alirocumab, evolocumab): Monoclonal antibodies that can lower LDL‑C by 50‑60 % and are especially useful in homozygous FH or statin‑intolerant patients.
• Bile‑acid sequestrants (cholestyramine, colesevelam): Useful adjuncts, particularly in children.
• Lipoprotein apheresis: Mechanical removal of LDL particles; reserved for severe homozygous FH or refractory cases.

Non‑pharmacologic measures

• Dietary modification: Plant‑sterol/stanol enriched foods, < 7 % of calories from saturated fat, avoidance of trans fats, increased soluble fiber (oats, legumes).
• Physical activity: ≥ 150 min/week of moderate‑intensity aerobic exercise.
• Weight management: Target BMI < 25 kg/m².
• Smoking cessation.

Procedural options for existing xanthomas

• Surgical excision: Considered when lesions cause functional limitation, pain, or cosmetic concerns, and when LDL‑C is well‑controlled.
• Laser therapy (CO₂ or Nd:YAG): Can improve superficial plane xanthomas but does not treat the underlying lipid disorder.
• Cryotherapy or radiofrequency ablation: Limited evidence; used in select dermatology centers.

Monitoring

• Check lipid panel 4–12 weeks after initiating or changing therapy, then every 3–6 months.
• Annual cardiovascular risk assessment (ECG, stress testing, or imaging as indicated).

Living with Xanthomatosis (familial)

Beyond medication, daily habits shape long‑term outcomes.

• Medication adherence: Use pillboxes or smartphone reminders; discuss side‑effects promptly.
• Family screening: First‑degree relatives should be tested; early detection can prevent complications.
• Skin care: Protect xanthomas from friction or trauma; moisturize to avoid cracking.
• Psychosocial support: Visible lesions may affect self‑esteem; counseling or support groups (e.g., FH Foundation) can help.
• Nutrition planning: Work with a registered dietitian experienced in lipid disorders.
• Exercise safety: Warm up gradually; avoid high‑impact activities that may irritate tendon xanthomas.

Prevention

Because the disorder is genetic, primary prevention of the disease itself is not possible, but many steps can reduce the severity of manifestations.

• Early detection: Newborn screening programs (in some regions) and cascade testing of families identify carriers before lesions develop.
• Start lipid‑lowering therapy early: Pediatric guidelines recommend statins from age 8‑10 for heterozygous FH.
• Maintain a heart‑healthy lifestyle throughout life to keep LDL‑C as low as possible.
• Vaccinations: Influenza and pneumococcal vaccines lower the risk of infections that may destabilize atherosclerotic plaques.

Complications

If left untreated or poorly controlled, familial xanthomatosis leads to serious health problems.

• Premature coronary artery disease: Leading cause of death; men may experience myocardial infarction before age 45, women before 55.
• Peripheral arterial disease and claudication.
• Stroke or transient ischemic attack.
• Aortic valve disease: Calcific aortic stenosis can develop earlier.
• Xanthoma ulceration or infection: Particularly with trauma.
• Psychological impact: Depression, anxiety, and social isolation due to visible lesions.

When to Seek Emergency Care

---

References
[1] Mayo Clinic. “Familial hypercholesterolemia.” Updated 2023.
[2] WHO. “Global Health Estimates: Cardiovascular diseases.” 2022.
[3] Nordestgaard BG, et al. “Familial hypercholesterolemia is underdiagnosed and undertreated in many countries.” J Clin Lipidol. 2020;14(3):429‑440.
[4] NIH National Heart, Lung, and Blood Institute. “LDL Cholesterol and Cardiovascular Disease.” 2021.
[5] American Heart Association. “2019 Guideline on the Treatment of Blood Cholesterol.”
[6] FH Foundation. “Cascade Screening Guidelines.” 2022.

```